- Home
- SD vs RGNX Comparison
SD vs RGNX Comparison
Compare SD & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- RGNX
- Stock Information
- Founded
- SD 2006
- RGNX 2008
- Country
- SD United States
- RGNX United States
- Employees
- SD N/A
- RGNX N/A
- Industry
- SD Oil & Gas Production
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SD Energy
- RGNX Health Care
- Exchange
- SD Nasdaq
- RGNX Nasdaq
- Market Cap
- SD 380.4M
- RGNX 451.1M
- IPO Year
- SD 2007
- RGNX 2015
- Fundamental
- Price
- SD $11.45
- RGNX $9.48
- Analyst Decision
- SD
- RGNX Strong Buy
- Analyst Count
- SD 0
- RGNX 8
- Target Price
- SD N/A
- RGNX $28.50
- AVG Volume (30 Days)
- SD 289.7K
- RGNX 645.3K
- Earning Date
- SD 11-05-2025
- RGNX 11-05-2025
- Dividend Yield
- SD 4.20%
- RGNX N/A
- EPS Growth
- SD 86.17
- RGNX N/A
- EPS
- SD 2.03
- RGNX N/A
- Revenue
- SD $146,165,000.00
- RGNX $155,782,000.00
- Revenue This Year
- SD $30.71
- RGNX $260.25
- Revenue Next Year
- SD $10.06
- RGNX N/A
- P/E Ratio
- SD $5.64
- RGNX N/A
- Revenue Growth
- SD 13.89
- RGNX 74.95
- 52 Week Low
- SD $8.81
- RGNX $5.04
- 52 Week High
- SD $13.19
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- SD 53.06
- RGNX 57.35
- Support Level
- SD $11.47
- RGNX $8.68
- Resistance Level
- SD $12.16
- RGNX $9.97
- Average True Range (ATR)
- SD 0.31
- RGNX 0.50
- MACD
- SD -0.02
- RGNX 0.11
- Stochastic Oscillator
- SD 54.37
- RGNX 77.10
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.